Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019030313) OLIGONUCLEOTIDES FOR MODULATING UBE3C EXPRESSION
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/030313 International Application No.: PCT/EP2018/071597
Publication Date: 14.02.2019 International Filing Date: 09.08.2018
IPC:
C12N 15/11 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
Applicants:
ROCHE INNOVATION CENTER COPENHAGEN A/S [DK/DK]; Fremtidsvej 3 2970 Horsholm, DK
Inventors:
HAGEDORN, Peter; DK
PEDERSEN, Lykke; DK
Agent:
RUDOLPH HANSEN, Marianneno; CH
TURNER, Mark; CH
BANHOLZER, Vivien; CH
Priority Data:
17185951.511.08.2017EP
Title (EN) OLIGONUCLEOTIDES FOR MODULATING UBE3C EXPRESSION
(FR) OLIGONUCLÉOTIDES POUR LA MODULATION DE L'EXPRESSION DE UBE3C
Abstract:
(EN) The present invention relates to antisense oligonucleotides that are capable of modulating expression of UBE3C in a target cell. The oligonucleotides hybridize to UBE3C pre-m RNA, preferably at repeated target sites. The present invention further relates to conjugates of the oligonucleotide and pharmaceutical compositions and methods for treatment of proliferatory or inflammatory disorders using the oligonucleotides.
(FR) La présente invention concerne des oligonucléotides antisens qui sont capables de moduler l'expression de UBE3C dans une cellule cible. Les oligonucléotides s'hybrident à l'ARN pré-messager de UBE3C, de préférence à des sites cibles répétés. La présente invention concerne également des conjugués de l'oligonucléotide ainsi que des compositions pharmaceutiques et des procédés de traitement du cancer, de l'inflammation ou de troubles prolifératifs ou inflammatoires au moyen des oligonucléotides.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)